Preclinical Study of Ar senic Tr ioxide in the Treatment of Solid Tumor
Date Issued
1998-07-31
Date
1998-07-31
Author(s)
陳耀昌
DOI
872314B002079
Abstract
Arsenic is a ubiquitous element in
environment. Chronic exposure of arsenic
compound may cause various diseases and is
also associated with increased risk of skin
cancer, lung cancer, bladder cancer. Despite
these chronic toxicity, arsenic is an ancient
medication and was used widely in both
western and Chinese medicine. It has been
used to treat asthma, arthritis and several
types of cancer, including leukemias.
Arsenic trioxide has revived after the
revelation that it is very effective in the
treatment of acute promyelocytic leukemia
patients who were refractory to both
chemotherapy and all-trans retinoic acid.
Our preliminary cytotoxicity results
indicated that at concentrations attainable in
patient plasma, As2O3 may inhibit the growth
of some solid tumor cell lines.
The objective of this project is to test
feasibility of using As2O3 in the treatment of
solid tumors. The secondary aim is to find
out mechanisms of toxicity and resistance of
tumor cells to arsenic compounds.
In this study, we found that As2O3 is very
cytotoxic to bladder cancer and APL cells. It
is moderately active in ovarian and
gastrointestinal cancer cells. Other types of
cancer are resistant to As2O3. As2O3 seems to
kill tumor cells through induction of
apoptosis. Our results indicate that it is
warranted to use As2O3 in clinical trials to
treat solid cancer patients, especially for
bladder cancer. High GSH content was
associated with intrinsic arsenic resistance in
cancer cells. BSO may be considered to
enhance cytotoxicity of arsenic treatment.
Subjects
氧化砷
癌症治療
抗藥性
SDGs
Publisher
臺北市：國立臺灣大學醫學院檢驗醫學科
Type
journal article
File(s)![Thumbnail Image]()
Loading...
Name
872314B002079.pdf
Size
43.07 KB
Format
Adobe PDF
Checksum
(MD5):c7484562ec5ce40e48258e13a399c26a